Cargando…
Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study
BACKGROUND: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686345/ https://www.ncbi.nlm.nih.gov/pubmed/34930444 http://dx.doi.org/10.1186/s13195-021-00938-w |
_version_ | 1784617999529934848 |
---|---|
author | Schneider, Lon S. Qiu, Yuqi Thomas, Ronald G. Evans, Carol Jacobs, Diane M. Jin, Shelia Kaye, Jeffrey A. LaCroix, Andrea Z. Messer, Karen Salmon, David P. Sano, Mary Schafer, Kimberly Feldman, Howard H. |
author_facet | Schneider, Lon S. Qiu, Yuqi Thomas, Ronald G. Evans, Carol Jacobs, Diane M. Jin, Shelia Kaye, Jeffrey A. LaCroix, Andrea Z. Messer, Karen Salmon, David P. Sano, Mary Schafer, Kimberly Feldman, Howard H. |
author_sort | Schneider, Lon S. |
collection | PubMed |
description | BACKGROUND: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the impact of exigent modifications due to COVID-19, we examined several scenarios in symptomatic and disease modification trials that could be made. METHODS: We identified both symptomatic and disease modification Alzheimer disease RCTs as exemplars of those that would be affected by the pandemic and considered the types of changes that sponsors could make to each. We modeled three scenarios for each of the types of trials using existing datasets, adjusting enrollment, follow-ups, and dropouts to examine the potential effects COVID-19-related changes. Simulations were performed that accounted for completion and dropout patterns using linear mixed effects models, modeling time as continuous and categorical. The statistical power of the scenarios was determined. RESULTS: Truncating both symptomatic and disease modification trials led to underpowered trials. By contrast, adapting the trials by extending the treatment period, temporarily stopping treatment, delaying outcomes assessments, and performing remote assessment allowed for increased statistical power nearly to the level originally planned. DISCUSSION: These analyses support the idea that disrupted trials under common scenarios are better continued and extended even in the face of dropouts, treatment disruptions, missing outcomes, and other exigencies and that adaptations can be made that maintain the trials’ validity. We suggest some adaptive methods to do this noting that some changes become under-powered to detect the original effect sizes and expected outcomes. These analyses provide insight to better plan trials that are resilient to unexpected changes to the medical, social, and political milieu. |
format | Online Article Text |
id | pubmed-8686345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86863452021-12-20 Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study Schneider, Lon S. Qiu, Yuqi Thomas, Ronald G. Evans, Carol Jacobs, Diane M. Jin, Shelia Kaye, Jeffrey A. LaCroix, Andrea Z. Messer, Karen Salmon, David P. Sano, Mary Schafer, Kimberly Feldman, Howard H. Alzheimers Res Ther Research BACKGROUND: The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries risks for biases and threats to validity. To understand the impact of exigent modifications due to COVID-19, we examined several scenarios in symptomatic and disease modification trials that could be made. METHODS: We identified both symptomatic and disease modification Alzheimer disease RCTs as exemplars of those that would be affected by the pandemic and considered the types of changes that sponsors could make to each. We modeled three scenarios for each of the types of trials using existing datasets, adjusting enrollment, follow-ups, and dropouts to examine the potential effects COVID-19-related changes. Simulations were performed that accounted for completion and dropout patterns using linear mixed effects models, modeling time as continuous and categorical. The statistical power of the scenarios was determined. RESULTS: Truncating both symptomatic and disease modification trials led to underpowered trials. By contrast, adapting the trials by extending the treatment period, temporarily stopping treatment, delaying outcomes assessments, and performing remote assessment allowed for increased statistical power nearly to the level originally planned. DISCUSSION: These analyses support the idea that disrupted trials under common scenarios are better continued and extended even in the face of dropouts, treatment disruptions, missing outcomes, and other exigencies and that adaptations can be made that maintain the trials’ validity. We suggest some adaptive methods to do this noting that some changes become under-powered to detect the original effect sizes and expected outcomes. These analyses provide insight to better plan trials that are resilient to unexpected changes to the medical, social, and political milieu. BioMed Central 2021-12-20 /pmc/articles/PMC8686345/ /pubmed/34930444 http://dx.doi.org/10.1186/s13195-021-00938-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Schneider, Lon S. Qiu, Yuqi Thomas, Ronald G. Evans, Carol Jacobs, Diane M. Jin, Shelia Kaye, Jeffrey A. LaCroix, Andrea Z. Messer, Karen Salmon, David P. Sano, Mary Schafer, Kimberly Feldman, Howard H. Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study |
title | Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study |
title_full | Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study |
title_fullStr | Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study |
title_full_unstemmed | Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study |
title_short | Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study |
title_sort | impact of potential modifications to alzheimer’s disease clinical trials in response to disruption by covid-19: a simulation study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686345/ https://www.ncbi.nlm.nih.gov/pubmed/34930444 http://dx.doi.org/10.1186/s13195-021-00938-w |
work_keys_str_mv | AT schneiderlons impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT qiuyuqi impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT thomasronaldg impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT evanscarol impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT jacobsdianem impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT jinshelia impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT kayejeffreya impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT lacroixandreaz impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT messerkaren impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT salmondavidp impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT sanomary impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT schaferkimberly impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy AT feldmanhowardh impactofpotentialmodificationstoalzheimersdiseaseclinicaltrialsinresponsetodisruptionbycovid19asimulationstudy |